Literature DB >> 12911622

Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease.

Baptiste A Faucheux1, Marie-Elise Martin, Carole Beaumont, Jean-Jacques Hauw, Yves Agid, Etienne C Hirsch.   

Abstract

Degeneration of dopaminergic neurones during Parkinson's disease is most extensive in the subpopulation of melanized-neurones located in the substantia nigra pars compacta. Neuromelanin is a dark pigment produced in the dopaminergic neurones of the human substantia nigra and has the ability to bind a variety of metal ions, especially iron. Post-mortem analyses of the human brain have established that oxidative stress and iron content are enhanced in association with neuronal death. As redox-active iron (free Fe2+ form) and other transition metals have the ability to generate highly reactive hydroxyl radicals by a catalytic process, we investigated the redox activity of neuromelanin (NM)-aggregates in a group of parkinsonian patients, who presented a statistically significant reduction (- 70%) in the number of melanized-neurones and an increased non-heme (Fe3+) iron content as compared with a group of matched-control subjects. The level of redox activity detected in neuromelanin-aggregates was significantly increased (+ 69%) in parkinsonian patients and was highest in patients with the most severe neuronal loss. This change was not observed in tissue in the immediate vicinity of melanized-neurones. A possible consequence of an overloading of neuromelanin with redox-active elements is an increased contribution to oxidative stress and intraneuronal damage in patients with Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12911622     DOI: 10.1046/j.1471-4159.2003.01923.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  70 in total

Review 1.  γ-Glutamylamines and neurodegenerative diseases.

Authors:  Thomas M Jeitner; Kevin Battaile; Arthur J L Cooper
Journal:  Amino Acids       Date:  2012-03-10       Impact factor: 3.520

Review 2.  Functional effects of neuromelanin and synthetic melanin in model systems.

Authors:  K L Double
Journal:  J Neural Transm (Vienna)       Date:  2006-05-05       Impact factor: 3.575

3.  Effects of BT-melanin on recovery of operant conditioned reflexes in rats after ablation of the sensorimotor cortex.

Authors:  O V Gevorkyan; I B Meliksetyan; A S Ovsepyan; A S Sagiyan
Journal:  Neurosci Behav Physiol       Date:  2007-06

Review 4.  Neuromelanin of the human substantia nigra: an update.

Authors:  Fabio A Zucca; Emy Basso; Francesca A Cupaioli; Emanuele Ferrari; David Sulzer; Luigi Casella; Luigi Zecca
Journal:  Neurotox Res       Date:  2013-10-24       Impact factor: 3.911

Review 5.  Neurotoxicity Linked to Dysfunctional Metal Ion Homeostasis and Xenobiotic Metal Exposure: Redox Signaling and Oxidative Stress.

Authors:  Carla Garza-Lombó; Yanahi Posadas; Liliana Quintanar; María E Gonsebatt; Rodrigo Franco
Journal:  Antioxid Redox Signal       Date:  2018-03-28       Impact factor: 8.401

6.  Differential effect of nimodipine in attenuating iron-induced toxicity in brain- and blood-brain barrier-associated cell types.

Authors:  J A Lockman; W J Geldenhuys; K A Bohn; S F Desilva; D D Allen; C J Van der Schyf
Journal:  Neurochem Res       Date:  2011-09-21       Impact factor: 3.996

7.  T1rho and T2rho MRI in the evaluation of Parkinson's disease.

Authors:  I Nestrasil; S Michaeli; T Liimatainen; C E Rydeen; C M Kotz; J P Nixon; T Hanson; Paul J Tuite
Journal:  J Neurol       Date:  2010-01-08       Impact factor: 4.849

Review 8.  Iron accumulation in Parkinson's disease.

Authors:  Hideki Mochizuki; Toru Yasuda
Journal:  J Neural Transm (Vienna)       Date:  2012-10-16       Impact factor: 3.575

Review 9.  Metal ion physiopathology in neurodegenerative disorders.

Authors:  Silvia Bolognin; Luigi Messori; Paolo Zatta
Journal:  Neuromolecular Med       Date:  2009-11-28       Impact factor: 3.843

10.  Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle.

Authors:  Kristen A Malkus; Elpida Tsika; Harry Ischiropoulos
Journal:  Mol Neurodegener       Date:  2009-06-05       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.